Clinigen Group

Clinigen Group plc’s Idis Managed Access (MA) division and United Therapeutics Corporation have initiated a Managed Access program for UNITUXIN™ (dinutuximab) injection.

Unique patient organization-driven program is enabling people with Hereditary Angioedema who cannot access effective treatments to receive medication for the first time

Clinigen Group plc (‘Clinigen’, AIM: CLIN) today announce the initiation of a global access program in Europe for rociletinib (CO-1686) which is being developed for the treatment of advanced non-small cell lung cancer (NSCLC).

Unique patient organization-driven program will enable patients with hereditary angioedema (HAE) who cannot access effective treatments to receive medication for the first time

Burton-on-Trent, UK – 18 February 2015 – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM:CLIN) announces the latest program to be managed by Clinigen Global Access Programs (Clinigen GAP).

Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN) announced today the initiation of an international global access program for AstraZeneca’s investigational antibiotic, CAZ-AVI (ceftazidame-avibactam), through its specialist Clinigen...

Panel of industry experts chaired by SVP Clinigen Global Access Programs offers best practices for programs enabling access for patients with unmet medical needs

Burton-on-Trent, UK and Pisa, Italy – 14 April 2014 – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) and Abiogen Pharma SpA (‘Abiogen’) jointly announced today the initiation of a Named Patient Program, managed by Clinigen...